VideoViral Hepatitis and Liver DiseaseHEP DART 2017Short Duration DAA HCV Therapy: How Short Can We Go? | Shyam Kottilil, MD, PhDView Video
VideoViral Hepatitis and Liver DiseaseHEP DART 2017DAA Therapy and Reinfection Among People who Inject Drugs: Forming a Foundation for HCV Elimination | Jason GrebelyView Video
VideoViral Hepatitis and Liver DiseaseHEP DART 2017Liver Disease in Chinese-perspective from a Hepatologist | George Lau, MBBS, MRCP, FHKCP, FHKAM, MD, FRCPView Video
VideoViral Hepatitis and Liver DiseaseHEP DART 2017Access to HIV, HBV, and HCV Antiviral Agents Globally | John Martin, PhDView Video
VideoViral Hepatitis and Liver DiseaseHEP DART 2017Global Strategies to Eliminate Hepatitis B (ICE-HBV) | Peter RevillView Video
VideoViral Hepatitis and Liver DiseaseHEP DART 2017Consensus AASLD-EASL HBV Treatment Endpoint and HBV Cure Definition | Anna S. Lok, MD, DScView Video
VideoViral Hepatitis and Liver DiseaseHEP DART 2017The French and European Approach Towards Hepatitis Elimination | Tarik Asselah, MD, PhDView Video
VideoViral Hepatitis and Liver DiseaseHEP DART 2017Elimination of HCV: The DC Story | Henry Masur, MDView Video
VideoViral Hepatitis and Liver DiseaseHEP DART 2017Strategy for the Elimination of Hepatitis B and C (Academy of Medicine Report) | Andrew Aronsohn, MDView Video
MHMargaret HellardAM, MBBS, FRACP, FAFPHM, PhDVideoViral Hepatitis and Liver DiseaseHEP DART 2017Eliminating Hepatitis C by 2030 - Enhancing prevention care and treatment among people who inject drugs | Margaret Hellard, AM, MBBS, FRACP, FAFPHM, PhDView Video
CFCharles FlexnerMDVideoHIVHIV DART and Emerging Viruses 2018Polypharmacy in an aging population and implications for antiretroviral therapy | Charles Flexner, MDView Video
VideoHIVHIV DART and Emerging Viruses 2018A post-transcriptional feedback mechanism for noise suppression and fate stabilization | Leor Weinberger, PhDView Video
